CBFB::MYH11 Inversion(16), Quantitative Detection and Minimal Disease Risk Monitoring, qRT-PCR, Varies
Use
This test detects the CBFB::MYH11 gene fusion in patients with acute myeloid leukemia (AML) and provides minimal residual disease monitoring during the clinical and therapeutic course. It is useful at the time of diagnosis and for post-therapy monitoring, aiding in evaluating disease response and identifying relapse risk.
Special Instructions
Not provided.
Limitations
This assay will only detect the 3 major exon fusions of CBFB::MYH11, accounting for ≥95% of cases and will not detect rare fusion types (<5%). Gross hemolysis and inappropriate handling may lead to sample rejection. Interassay variability means result changes should not be considered significant if 2 measurements differ by less than 0.5 log unless accompanied by a change in positivity status or ≥1 log increase.
New York Approved
Methodology
PCR-based (qRT-PCR)
Biomarkers
No genes
Gene
LOINC Codes
- 101377-0 - inv(16)(p13;q22) Bld/Mar
- 31208-2 - Specimen source
- 59465-5 - Path Rev
- 19139-5 - Pathologist name
Result Turnaround Time
4-8 days
Related Documents
For more information, please review the documents below
Specimen
Whole Blood
Volume
10 mL
Minimum Volume
8 mL
Container
Lavender top (EDTA) or yellow top (ACD-B)
Collection Instructions
Invert several times to mix blood. Send whole blood specimen in original tube. Do not aliquot. Label specimen as blood.
Causes for Rejection
Gross hemolysis.
Stability Requirements
| Temperature | Period |
|---|---|
| Refrigerated | 5 days |